Exome sequencing of 628,388 individuals identifies common and rare variant associations with clonal hematopoiesis phenotypes
Michael D. KessleriD, Amy DamaskiD, Sean O’KeeffeiD, Michael Van Meter, Nilanjana BanerjeeiD, Stefan Semrau, Dadong LiiD, Kyoko WatanabeiD, Julie E. HorowitziD, Yariv J. HouvrasiD, Christopher E. GilliesiD, Joelle S. MbatchouiD, Ryan R. WhiteiD, Jack A. KosmickiiD, Michelle G. LeBlanciD, Marcus B. JonesiD, David J. GlassiD, Luca Andrea LottaiD, Michael N CantoriD, Gurinder S. AtwaliD, Adam E. LockeiD, Manuel A. R. FerreiraiD, Raquel P. DeeringiD, Charles PauldingiD, Alan R. ShuldineriD, , Eric JorgensoniD
Abstract
Clonal hematopoiesis (CH) refers to the expansion of certain blood cell lineages and has been associated with aging and adverse health outcomes. Here, we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal hematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 27 loci (24 novel) where germline genetic variation influences CH/CHIP predisposition, including missense variants in the DNA-repair gene PARP1 and the lymphocytic antigen coding gene LY75 that are associated with reduced incidence of CH/CHIP. Analysis of 5,194 health traits from the UK Biobank (UKB) found relationships between CHIP and severe COVID outcomes, cardiovascular disease, hematologic traits, malignancy, smoking, obesity, infection, and all-cause mortality. Longitudinal analyses revealed that one of the CHIP subtypes, DNMT3A-CHIP, is associated with the subsequent development of myeloid but not lymphoid leukemias, and with solid cancers including prostate and lung. Additionally, contrary to previous findings from the initial 50,000 UKB exomes, our results in the full sample do not support a role for IL-6 inhibition in reducing the risk of cardiovascular disease among CHIP carriers. Our findings demonstrate that CHIP represents a complex set of heterogenous phenotypes with shared and unique germline genetic causes and varied clinical implications.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 21
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genomic and phenomic landscape of clonal hematopoiesis in over a million ancestrally diverse participants
Md Mesbah Uddin, Zhi Yu, … Pradeep Natarajan·medRxiv·Jul 29, 2022
- Inherited Causes of Clonal Hematopoiesis of Indeterminate Potential in TOPMed Whole Genomes
Alexander G. Bick, Joshua S. Weinstock, … Eric Boerwinkle·bioRxiv·Sep 27, 2019
- Shared and distinct genetic etiologies for different types of clonal hematopoiesis
Derek W. Brown, Liam D. Cato, … Mitchell J. Machiela·Nature CommunicationsPeer-reviewed·Sep 8, 2023
- The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Myvizhi Esai Selvan, Namira Ashraf, … Zeynep Hulya Gumus·medRxiv·Oct 26, 2026
- Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds
Christelle Colin, Yi-Han Tang, … Nancy Gillis·medRxiv·Mar 21, 2025
- Unified somatic calling and machine learning-based classification enhance the discovery of clonal hematopoiesis of indeterminate potential
Shulan Tian, Garrett Jenkinson, … Eric W. Klee·bioRxiv·Apr 22, 2024